PXS.AU · Pharmaxis Ltd

-

Please sign in to comment on PXS.AU

1 Comment

Admin

4 years, 1 month ago

Pharmaxis Ltd is currently in a long term downtrend where the price is trading 2.1% below its 200 day moving average.

From a valuation standpoint, the stock is 98.2% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 4.7.

Pharmaxis Ltd's total revenue rose by 256.4% to $13M since the same quarter in the previous year.

Its net income has increased by 100.4% to $46K since the same quarter in the previous year.

Finally, its free cash flow grew by 278.9% to $9M since the same quarter in the previous year.

Based on the above factors, Pharmaxis Ltd gets an overall score of 4/5.

Exchange	AU
CurrencyCode	AUD
Sector	Healthcare
Industry	Drug Manufacturers - Specialty & Generic
ISIN	AU000000PXS5

Market Cap	20M
PE Ratio	None
Target Price	0.14
Beta	0.64
Dividend Yield	None

ABOUT

Pharmaxis Ltd

Syntara Limited operates as a clinical stage drug development company that focuses on blood-related cancers. Its lead product candidate is PXS-5505, which is in phase 2 trial for the bone marrow cancer myelofibrosis, which causes a build-up of scar tissue leading to loss of red and white blood cells and platelets. The company was formerly known as Pharmaxis Ltd and changed its name to Syntara Limited in December 2023. Syntara Limited was incorporated in 1998 and is headquartered in Frenchs Forest, Australia.

PXS.AU · Pharmaxis Ltd

-

Pharmaxis Ltd

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Pharmaxis Ltd using a moving average strategy